OncoMatch/Clinical Trials/NCT06785415
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Is NCT06785415 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Daratumumab and Elotuzumab for recurrent multiple myeloma.
Treatment: Daratumumab · Dexamethasone · Elotuzumab · Iberdomide — This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Elotuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving iberdomide in combination with daratumumab, elotuzumab, and dexamethasone may be safe, tolerable and/or effective in patients with relapsed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor (ixazomib, carfilzomib, bortezomib)
including treatment with proteasome inhibitors (i.e., ixazomib, carfilzomib, bortezomib)
Must have received: immunomodulatory imide drug (lenalidomide, pomalidomide)
immunomodulatory imide drugs (i.e., lenalidomide, pomalidomide)
Must have received: anti-CD38 drug (daratumumab, isatuximab)
anti-CD38 drugs (i.e., daratumumab, isatuximab)
Cannot have received: immunomodulatory imide drug (iberdomide)
Prior treatment with iberdomide is not allowed
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL; ANC ≥ 1000/m^3; Platelet count ≥ 50,000/mm^3 (no transfusions to achieve minimum)
Kidney function
Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for patients with Gilbert's syndrome); ALT and AST ≤ 2 x ULN; alkaline phosphatase ≤ 1.5 x ULN
Cardiac function
No current clinically significant uncontrolled arrhythmias, no history of MI/ACS/angioplasty/stenting/bypass ≤ 3 months, no NYHA class III/IV heart failure, no uncontrolled hypertension, no history of life-threatening ventricular arrhythmias
Hemoglobin ≥ 8.0 g/dL (obtained ≤14 days prior to registration). ANC ≥ 1000/m^3 (obtained ≤14 days prior to registration). Platelet count ≥ 50,000/mm^3. Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for patients with Gilbert's syndrome). ALT and AST ≤ 2 x ULN and alkaline phosphatase ≤ 1.5 x ULN. Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault. Evidence of cardiovascular disease risk, as defined by any of the following: Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree AV block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting ≤ three (3) months prior to registration; Class III or IV heart failure as defined by the New York Heart Association functional classification system [NYHA, 1994]; Uncontrolled hypertension; History of life-threatening ventricular arrhythmias.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify